These subtypes exhibit different histopathological features and treatment sensitivities.7 Patients with luminal breast cancer often have a better prognosis, whereas those with HER2‐enriched or basal‐like types have a poorer prognosis. This evidence concerns the gene ERBB2 and breast cancer.